Returning guest, Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses new data presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) that strengthen the value of the Oncotype DX ® Breast Recurrence Score test as well as other data supporting their precision portfolio. He talks about Exact Science’s role in helping breast cancer patients make informed decisions about treatment and shares an update around a new test the company just launched that aids in therapy selection for advanced cancers.

Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop and commercialize the Oncotype DX ® breast cancer, colon cancer, prostate cancer and liquid biopsy assays.

Liked it? Take a second to support healthprofessionalradio on Patreon!